Bellicum Pharmacueticals Inc. (NASDAQ:BLCM)’s share price rose 8.7% during mid-day trading on Friday . The stock traded as high as $17.93 and last traded at $17.57, with a volume of 231,683 shares. The stock had previously closed at $16.17.

BLCM has been the topic of several research reports. SunTrust Banks Inc. initiated coverage on Bellicum Pharmacueticals in a research note on Thursday, June 2nd. They set a “buy” rating and a $20.00 target price on the stock. Zacks Investment Research raised Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research report on Monday, July 11th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Bellicum Pharmacueticals in a research report on Saturday, July 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $27.50.

The company’s market cap is $468.44 million. The stock’s 50 day moving average price is $13.96 and its 200-day moving average price is $11.31.

Bellicum Pharmacueticals (NASDAQ:BLCM) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.07. On average, equities research analysts expect that Bellicum Pharmacueticals Inc. will post ($2.22) earnings per share for the current fiscal year.

In other news, insider David M. Spencer sold 10,000 shares of Bellicum Pharmacueticals stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $15.00, for a total value of $150,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CTO Kevin M. Slawin sold 2,719 shares of Bellicum Pharmacueticals stock in a transaction on Monday, July 18th. The shares were sold at an average price of $13.99, for a total value of $38,038.81. Following the completion of the sale, the chief technology officer now directly owns 134,206 shares of the company’s stock, valued at approximately $1,877,541.94. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Bellicum Pharmacueticals stock. Morgan Stanley raised its position in shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned about 1.61% of Bellicum Pharmacueticals worth $8,653,000 at the end of the most recent reporting period.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.